Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Balance Therapeutics Stock

Q: How to sell Balance Therapeutics stock?

If you hold private company shares of Balance Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Balance Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

balance-therapeutics.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $57.17MM

Balance Therapeutics Inc is a biotechnology company addressing conditions of intellectual disability.

Buy or sell Balance Therapeutics stockLearn more about Balance Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access Balance Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Balance Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Lyndon Lien Ph.D

President, Chief Executive Officer and Board Member

Xiao-Xiong Lu Ph.D

Vice President, Technical Operations

Herb Cross

Chief Financial Officer

Board Members

Carl Gordon Ph.D

OrbiMed

Michael Grey

Pappas Capital

Ernest Mario Ph.D

Pappas Capital

Richard Chin MD

Lyndon Lien Ph.D

Peter Carlton

Oakmont (Los Angeles)

Balance Therapeutics stock FAQs

Can you buy Balance Therapeutics stock?

As Balance Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Balance Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Balance Therapeutics stock?

To invest in a private company like Balance Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Balance Therapeutics stock?

Yes, you may be able to sell your Balance Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Balance Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Balance Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Balance Therapeutics a public company?

No, Balance Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Balance Therapeutics’ stock price?

Balance Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Balance Therapeutics’ private market stock price with Forge Data.

What is Balance Therapeutics’ stock ticker symbol?

Balance Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Stock Analysis 11/29/2023

Baby registry megasite Babylist opening first retail store

Sarepta Therapeutics has a healthy balance sheet, according to an analysis by Simply Wall St. As of September 2023, the company held $1.24bn of debt, down from $1.54bn a year prior, and $1.73bn of cash. While the firm reported revenue of $1.1bn over the past year, up 26%, it did not report any earnings before interest and tax, indicating it is yet to reach profitability. The company's revenue growth suggests it may be in a position to turn a profit in the future.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.